Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Top 10 News for 4/20 - 4/24: Comcast Cancels Time Warner Deal; Teva/Mylan/Perrigo Saga Continues; Big Names, Solid Earnings
- Comcast (CMCSA) Terminates Time Warner Cable (TWC) Merger Agreement (CHTR)
- Amazon.com (AMZN) Tops Q1 EPS by 1c, Sales Beat
- Mylan (MYL) to Begin Cash, Stock Tender of Perrigo (PRGO)
- Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inotek (ITEK) Surges on Peer's Trial Failure
- Dicerna Pharma (DRNA) Receives FDA Orphan Drug Designation for PH1 Therapeutic Candidate
- Cipher Pharma (CPHR) Issues Positive Update on Ranbaxy Markman Hearing
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!